The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Newer treatments for advanced hepatocellular carcinoma

  • Song, Myeong Jun (Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Bae, Si Hyun (Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • Received : 2014.02.18
  • Accepted : 2014.02.18
  • Published : 2014.03.01
⟨ Previous Next ⟩

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options are needed for patients with advanced HCC. The current standard treatment for patients with advanced HCC, according to the Barcelona Clinic Liver Cancer staging system, is the multikinase inhibitor sorafenib. Other alternative therapies are required, due to the limited treatment response to, and tolerance of, this molecular target agent. Clinical trials of hepatic artery infusion chemotherapy, radioembolization, and multimodal treatments have shown favorable results in advanced HCC patients. This article introduces new treatment modalities for advanced HCC and discusses future therapeutic possibilities.

Keywords

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. https://doi.org/10.3322/canjclin.55.2.74
  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917. https://doi.org/10.1016/S0140-6736(03)14964-1
  3. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. https://doi.org/10.1002/hep.20933
  4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. https://doi.org/10.1056/NEJMoa0708857
  5. Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012;48:1452-1465. https://doi.org/10.1016/j.ejca.2011.12.006
  6. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  7. Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol 2008;19:847-851. https://doi.org/10.1093/annonc/mdm528
  8. Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464-473.
  9. Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013;269:603-611. https://doi.org/10.1148/radiol.13130150
  10. Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 2012;82:2004-2011. https://doi.org/10.1016/j.ijrobp.2011.03.019
  11. Kudo M. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Dig Dis 2011;29:289-302. https://doi.org/10.1159/000327562
  12. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-3140. https://doi.org/10.1158/1535-7163.MCT-08-0013
  13. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-474. https://doi.org/10.1007/s12072-010-9165-7
  14. Lee HC. Systemic chemotherapy of hepatocellular carcinoma: Korean experience. Oncology 2008;75 Suppl 1:114-118. https://doi.org/10.1159/000173432
  15. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-165.
  16. Kim HY, Kim JD, Bae SH, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010;16:355-361. https://doi.org/10.3350/kjhep.2010.16.4.355
  17. Ishikawa T, Imai M, Kamimura H, et al. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007;13:5465-5470. https://doi.org/10.3748/wjg.v13.i41.5465
  18. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008;38:474-483. https://doi.org/10.1111/j.1872-034X.2008.00338.x
  19. Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 2010;78 Suppl 1:142-147. https://doi.org/10.1159/000315243
  20. Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2012;42:340-348. https://doi.org/10.1111/j.1872-034X.2011.00938.x
  21. Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999;5:2620-2628.
  22. Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011;137:659-667. https://doi.org/10.1007/s00432-010-0917-5
  23. Itamoto T, Nakahara H, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 2002;80:143-148. https://doi.org/10.1002/jso.10116
  24. Murata K, Shiraki K, Kawakita T, et al. Low-dose chemotherapy of cisplatin and 5-f luorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 2003;23(2C):1719-1722.
  25. Woo HY, Bae SH, Park JY, et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010;65:373-382. https://doi.org/10.1007/s00280-009-1126-2
  26. Strigari L, Sciuto R, Rea S, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377-1385. https://doi.org/10.2967/jnumed.110.075861
  27. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293-298.
  28. Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med 2011;25:455-461. https://doi.org/10.1007/s12149-011-0499-6
  29. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68:13-23. https://doi.org/10.1016/j.ijrobp.2006.11.060
  30. Wang SC, Bester L, Burnes JP, et al. Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010;54:178-187. https://doi.org/10.1111/j.1754-9485.2010.02167.x
  31. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81.
  32. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-1837. https://doi.org/10.1002/hep.26014
  33. Kim DY, Park BJ, Kim YH, et al. Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am J Clin Oncol 2013 Sep 21 [Epub]. http://dx.doi.org/10.1097/COC.0b013e3182a78dba.
  34. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium- 90 microspheres: a comprehensive report of longterm outcomes. Gastroenterology 2010;138:52-64. https://doi.org/10.1053/j.gastro.2009.09.006
  35. Cabibbo G, Latteri F, Antonucci M, Craxi A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009;6:159-169. https://doi.org/10.1038/ncpgasthep1357
  36. Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 2004;10:1885-1889. https://doi.org/10.3748/wjg.v10.i13.1885
  37. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037-2044.
  38. Seong J, Park HC, Han KH, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003;27:30-35. https://doi.org/10.1016/S1386-6346(03)00162-1
  39. Park MS, Kim SU, Park JY, et al. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol 2013;71:165-173. https://doi.org/10.1007/s00280-012-1993-9
  40. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965;93:200-208.
  41. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-1248. https://doi.org/10.1016/0360-3016(94)00418-K
  42. Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology 2011;81 Suppl 1:123-133. https://doi.org/10.1159/000333275

Cited by

  1. Ethyl acetate extract from Jiedu Xiaozheng Yin inhibits the proliferation of human hepatocellular carcinoma cells by suppressing polycomb gene product Bmi1 and Wnt/β-catenin signaling vol.32, pp.6, 2014, https://doi.org/10.3892/or.2014.3541
  2. Cavitary Form of Lung Metastasis from Advanced Hepatocellular Carcinoma vol.88, pp.2, 2014, https://doi.org/10.3904/kjm.2015.88.2.202
  3. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma vol.21, pp.13, 2014, https://doi.org/10.3748/wjg.v21.i13.3843
  4. Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential vol.2016, pp.None, 2014, https://doi.org/10.1155/2016/5735869
  5. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways vol.7, pp.24, 2016, https://doi.org/10.18632/oncotarget.9168
  6. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway vol.48, pp.1, 2014, https://doi.org/10.3892/ijo.2015.3250
  7. Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma vol.11, pp.1, 2014, https://doi.org/10.3892/ol.2015.3859
  8. Investigation of quercetin‐induced HepG2 cell apoptosis‐associated cellular biophysical alterations by atomic force microscopy vol.38, pp.2, 2016, https://doi.org/10.1002/sca.21245
  9. Endocan silencing induces programmed cell death in hepatocarcinoma vol.14, pp.5, 2014, https://doi.org/10.3892/ol.2017.6857
  10. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance vol.77, pp.3, 2014, https://doi.org/10.1080/00365513.2017.1286684
  11. Hepatocellular Carcinoma: Implications for Asia-Pacific Oncology Nurses vol.4, pp.2, 2017, https://doi.org/10.4103/2347-5625.204497
  12. Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches vol.22, pp.3, 2014, https://doi.org/10.3233/cbm-171160
  13. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma : A STROBE-compliant article vol.97, pp.17, 2014, https://doi.org/10.1097/md.0000000000010611
  14. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma vol.29, pp.6, 2018, https://doi.org/10.1097/cad.0000000000000616
  15. Autophagy in Hepatocellular Carcinoma-29 after Single or Combined Administration of Lithium Carbonate and Rapamycin vol.13, pp.5, 2014, https://doi.org/10.1134/s1990519x19050079
  16. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis vol.64, pp.12, 2014, https://doi.org/10.1007/s10620-019-05701-8
  17. Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observa vol.24, pp.3, 2020, https://doi.org/10.14701/ahbps.2020.24.3.243
  18. CC Chemokine Ligand 17 Promoted Cell Metastasis via Tumor Necrosis Factorα/Nuclear Factor Kappa-B Signaling Pathway vol.11, pp.2, 2014, https://doi.org/10.1166/jbt.2021.2540